HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 6,301-6,312 of 27,277
Drug study icon
CompletedNCT00554177

A study for PTSD

Official study title

Mifepristone After Trauma to Enhance Resilience

This study has finished and is no longer accepting participants.

In New York
PTSDMedication studyAges 18–65
Countries
United States
Sponsor
Antonia New
Drug study icon
CompletedNCT00571922

A study of Acamprosate for Treatment of Methamphetamine Addiction

Official study title

A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence

This study has finished and is no longer accepting participants.

In New York
AddictionMedication studyAges 18–99
Countries
United States
Sponsor
NYU Langone Health
Drug study icon
Active Not RecruitingNCT07396272

A study of Add-on Oral Slow-release Ketamine Treatment in Major Depression

Official study title

A Pilot, Open-label Phase II Trial of Adjunctive Treatment With Ketamine Hydrochloride Prolonged-Release Tablets (KET01) During the Initiation of Antidepressant Therapy in Major Depressive Disorder

This study is no longer accepting new participants.

In Lund
DepressionMedication studyAges 18–75
Countries
Sweden
Sponsor
Daniel Lindqvist
Drug study icon
CompletedNCT02002832

A study of Lurasidone in Treatment of Schizophrenia

Official study title

A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Behavioral study icon
Active Not RecruitingACTRN12612000951853

A study of Mentalization Based Therapy treatment for Borderline Personality disorder

Official study title

Outcome effects of a Mentalization Based Treatment service (Mindsight) for people with Borderline Personality disorder in urban Christchurch: a clinical trial and evaluative study

This study is no longer accepting new participants.

In New Zealand
Personality disordersInterventional studyAges 18+
Countries
New Zealand
Sponsor
University of Otago, Christchurch
Drug study icon
CompletedNCT03460756

A study of Oral Ganaxolone in Women With Postpartum Depression

What is this study about?

This study evaluated the safety and effectiveness of Ganaxolone for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale
DepressionMedication studyAges 18–48
Countries
United States
Sponsor
Marinus Pharmaceuticals
Drug study icon
TerminatedNCT05260541

A study of PRAX-114 in people with PTSD

What is this study about?

Researchers are comparing 60 mg PRAX-114 or 40 mg PRAX-114, 40 mg PRAX-114 and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

This study ended early.

Multiple locations, including Phoenix
PTSDMedication studyAges 18–65
Countries
United States
Sponsor
Praxis Precision Medicines
Drug study icon
CompletedNCT05624528

A study of Tolcapone in OCD

What is this study about?

Researchers compared Tolcapone and placebo to find out how the approaches affected obsessive thoughts and compulsive behaviours in people with OCD.

This study has finished and is no longer accepting participants.

In Chicago
OCDMedication studyAges 18–65
Countries
United States
Sponsor
University of Chicago
Device study icon
CompletedNCT02505126

A study on the Efficacy of tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients (REDSTIM)

Official study title

A Randomized Double-blind Clinical Trial on the Efficacy of Transcranial Direct Current Stimulation (tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder

This study has finished and is no longer accepting participants.

In Dijon
AddictionDevice studyAges 18+
Countries
France
Sponsor
Centre Hospitalier Universitaire Dijon
Drug study icon
CompletedNCT04865835

A study Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Official study title

A Randomized, Single-blind, Two-period Crossover to Investigate the Effect of SEP-363856 on the Pharmacokinetics of Metformin in Subjects With Schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Oakland Park
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.